← All trials
NCT00693849
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2008
- Primary completion
- Dec 1, 2017
- Completion date
- Apr 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 2688
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- BRC Operations Pty. Ltd.Lead sponsor
- Ohio State UniversityOverall official - principal investigator
- Stanford UniversityOverall official - principal investigator
- Flinders UniversityOverall official - principal investigator
- Cornell UniversityOverall official - principal investigator
- University of MiamiOverall official - principal investigator
- Brain Dynamics CentreOverall official - principal investigator
- Swinburne UniversityOverall official - principal investigator
- Shanti Clinical TrialsOverall official - principal investigator
- A.D.D. Treatment CenterOverall official - principal investigator
- Brainclinics Diagnostics B.V.Overall official - principal investigator
- Skyland Behavioral Health AssociatesOverall official - principal investigator
- Monash UniversityOverall official - principal investigator
- University of MissouriOverall official - principal investigator
- The Alfred HospitalOverall official - principal investigator
- University of AucklandOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.